Nephros, Inc. (NASDAQ:NEPH – Get Free Report) saw a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 5,000 shares, a decrease of 30.6% from the January 15th total of 7,200 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 10,900 shares, the short-interest ratio is currently 0.5 days.
Hedge Funds Weigh In On Nephros
A hedge fund recently bought a new stake in Nephros stock. Topline Capital Management LLC purchased a new position in shares of Nephros, Inc. (NASDAQ:NEPH – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 419,887 shares of the company’s stock, valued at approximately $617,000. Topline Capital Management LLC owned approximately 3.98% of Nephros at the end of the most recent quarter. 41.10% of the stock is currently owned by hedge funds and other institutional investors.
Nephros Stock Performance
Nephros stock traded down $0.04 during mid-day trading on Friday, reaching $1.52. 45,495 shares of the company were exchanged, compared to its average volume of 9,885. The business has a fifty day moving average of $1.56 and a 200 day moving average of $1.64. The firm has a market cap of $16.02 million, a P/E ratio of -16.89 and a beta of 1.19. Nephros has a 12-month low of $1.36 and a 12-month high of $3.73.
Analysts Set New Price Targets
Read Our Latest Stock Analysis on Nephros
About Nephros
Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.
Featured Stories
- Five stocks we like better than Nephros
- 3 Small Caps With Big Return Potential
- Symbotic Shares Down 37%—Is It Time for Bravery or Caution?
- Utilities Stocks Explained – How and Why to Invest in Utilities
- High-Yield Healthcare: 3 Stocks With Strong Dividends
- How to Calculate Options Profits
- Beyond the Bargain Bin: 3 Stocks Leading Discount Retail
Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.